LPL Financial’s Immune Pharmaceuticals Inc. IMNP Stock Holding History

LPL Financial’s Portfolio IMNP Stock Details IMNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,000	Closed	-$10K	–	3150
2016 Q1	$10K	Sell	1,000 -1,000	-50%	-$10.3K	﹤0.01%	3081
2015 Q4	$32K	Buy	+2,000	New	+$42K	﹤0.01%	3084

Other funds holding IMNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EEG

E.E. Geduld $178M AUM 29.34% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

IFS

Ifrah Financial Services Little Rock, Arkansas $409M AUM 28.15% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

LPL Financial's IMNP Position: Q2 2016 in Review

LPL Financial sold out of Immune Pharmaceuticals Inc. (IMNP) in Q2 2016, closing a stake of 1,000 shares — an estimated $10K sold.

LPL Financial first reported a position in IMNP in Q4 2015 and held it in 2 quarters. The position peaked at $32K in Q4 2015. 11 funds tracked by Wall St. Rank hold IMNP as of Q2 2016.

LPL Financial reported no remaining Immune Pharmaceuticals Inc. position as of Q2 2016 after selling out during the quarter.
LPL Financial sold 1,000 Immune Pharmaceuticals Inc. shares in Q2 2016, an estimated $10K.
LPL Financial first reported a position in Immune Pharmaceuticals Inc. in Q4 2015 and held it in 2 quarters.
LPL Financial's Immune Pharmaceuticals Inc. position peaked at $32K in Q4 2015.
11 funds tracked by Wall St. Rank held Immune Pharmaceuticals Inc. as of Q2 2016.

Based on LPL Financial's 13F filing for Q2 2016, filed 15 Aug 2016.